Risks associated with omega-3 supplementation
Risks associated with omega-3 supplementationDuring my preoperative visit, my surgeon handed me a list of no less then 165 medications and supplements that I should stop taking 14 days prior to my surgery. Fish and krill oil were on the list, as were aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)—as expected.
Antithrombotic therapy to prevent migraine attacks after ASD closureClopidogrel therapy can make a difference after ASD closures.
FDA expands Brilinta approval for long-term use in patients with heart attack historyFDA has expanded approval for ticagrelor (Brilinta, AstraZeneca) to include long-term use in patients with a history of heart attack.
Unichem recalls 1 lot of blood pressure drugUnichem Pharmaceuticals issued a voluntary recall of Hydrochlorothiazide Tablets 25 mg, 1,000-count bottle. The precautionary measure is due to the identification of a Clopidogrel tablet found in a bottle at one pharmacy.
Post-MI NSAID/anticoag combo may increase risk of CV bleeding eventsAmong patients receiving antithrombotic therapy (to prevent the formation of blood clots) after a heart attack, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of bleeding and events such as heart attack, stroke or cardiovascular death, even after short-term treatment, according to a study in the February 24 issue of JAMA.
[BLOG]: Cost containment through the use of generic medicationsThere’s no hiding that hospital pharmacies have long been considered cost centers for healthcare systems. That positioning has been accentuated over the past 5 years, as the healthcare industry has seen a steady increase in high-cost, brand-name specialty medications that range from hundreds to thousands, sometimes tens of thousands, of dollars per dose. Nearly every hospital, however, has untapped opportunities to substantially improve efficiencies and improve costs. One important factor is improving how these hospitals use generic medications.
FDA reviews trial results of long-term dual antiplatelet therapyFDA announced that it will review results from a clinical trial showing that long-term dual antiplatelet therapy decreased the risk of heart attacks and clot formation in stents, but there was an increased overall risk of death compared to 12 months of treatment.
[BLOG] The acute coronary syndrome pipeline: Novel therapies targeting unmet needs in niche patient populationsNot surprisingly, the treatment costs associated with ACS and its various comorbidities are astoundingly high.
Delay in filling clopidogrel prescription after coronary stent linked to adverse clinical outcomesA delay in filling the first prescription for clopidogrel after coronary stenting is associated with an increased risk of death and myocardial infarction (MI), according to a study published online May 28 in the Journal of the American Heart Association.
FDA approves clot-busting vorapaxarFDA approved vorapaxar (Zontivity, Merck Sharp & Dohme Corp., a subsidiary of Merck) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart attack or blockages in the arteries to the legs.